BMS Settles with California Insurance Commission – Seems Everyone Is…
Life sciences companies continue to be the target of whistleblower actions, not only on the federal level but the state level as…
Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
FDA Raises Issue of Citizen Petitions
In August, the FDA noted its concerns that citizen petitions do not raise valid scientific issues and are used to delay the…
House Ways and Means Subcommittee on Oversight Holds Hearing on Health Care…
On Wednesday, September 28, 2016, the House Ways and Means Oversight Subcommittee held a hearing on Health Care Fraud…
How Realistic is the Yates Memo after Acclarent?
There has been much hubbub around the Yates Memorandum and what it means for compliance officers, especially in the life sciences…
Life Science CEOs “Upbeat” About Industry Prospects
According to KPMG LLP’s U.S. CEO Outlook 2016, CEOs of life science companies are confident about their prospects for growth in…
Post ICD-10 Changes to the ACA and its Implications
The coming year will bring along change for practices. The ending of the ICD-10 grace period will bring rising problems for…
CMS Releases MA and Part D Landscape Information for 2017
On September 22, 2016, the Centers for Medicare and Medicaid Services (CMS) announced information on premiums and costs for…
NPAs and DPAs – An Enforcement Loophole or Compliance Incentive?
The U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (“SEC”) recently have faced criticism for…
Is Pricing the New Frontier?
“Usual and customary (U&C) pricing” can be a very confusing term, even to executives of specialty pharmacy companies. The term…
Opioids Under the Microscope – A Recap of Recent Events that Could…
Opioids are under the microscope by a variety of groups, including political and pharmaceutical organizations. Now, adding fuel to…